儿童慢性髓性白血病持续深度分子学缓解后停用伊马替尼:STOP IMAPED研究结果
这项国际研究评估了儿童慢性髓性白血病(CML)患者在持续深度分子学缓解(DMR)至少2年后停用伊马替尼的效果。14例患者入组,10例复发,所有分子学复发均发生在停药后6个月内(中位3个月,范围1-6个月),6个月维持DMR的总体概率为28.6%。
要点
- 14例儿童CML患者持续DMR至少2年后停用伊马替尼,10例出现分子学复发。
- 所有分子学复发均发生在停药后6个月内,中位3个月(范围1-6个月)。
- 6个月维持DMR的总体概率为28.6%,未发现与分子学复发相关的参数。
核心结论
- 在持续DMR后停用伊马替尼,仅在有限数量的儿童CML患者中获得成功,而成人患者报告的成功率要高得多。
- 需要进一步研究以扩大可能实现无治疗缓解的儿童CML患者队列,理想前提是预测停用伊马替尼后分子学复发的发生。
研究设计与样本
- 国际研究,旨在评估儿童CML患者在达到并维持DMR至少2年后停用伊马替尼的效果。
- 共入组14例患者;主要终点为6个月时无分子学复发的患者估计率,采用非参数Kaplan-Meier法估计分子学无复发生存。
主要发现
- 4例患者维持DMR,随访时间分别为24个月(2例)、34个月和66个月;10例患者复发。
- 所有分子学复发均发生在停用伊马替尼后6个月内(中位3个月,范围1-6个月)。
- 6个月维持DMR的总体概率为28.6%。
- 未发现与分子学复发相关的参数。
局限性
- 儿童CML罕见,导致队列规模小。
- 需要进一步研究以扩大可能实现无治疗缓解的儿童CML患者队列,理想前提是预测停用伊马替尼后分子学复发的发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This international study aimed to assess the effect of imatinib discontinuation in paediatric patients with chronic myeloid leukaemia (CML) after deep molecular remission (DMR) had been achieved and maintained for at least 2 years. The primary endpoint of this analysis was the molecular relapse-free survival, estimated by the non-parametric Kaplan-Meier method. Major endpoint was the estimated rate of patients without molecular relapse at 6 months. Fourteen patients were enrolled; 4 patients maintained DMR with a follow-up of 24 (two patients), 34 and 66 months, respectively, whereas 10 patients relapsed. All molecular relapses occurred within 6 months (median 3 months, range 1-6) after imatinib discontinuation. The overall probability of maintaining DMR at 6 months was 28·6%. No parameters associated with molecular relapse could be identified. Keeping in mind the rarity of paediatric CML, which contributed to the small size of the cohort, our findings illustrate that imatinib cessation after sustained DMR is successful in only limited numbers of patients, whereas much higher rates are reported in adult patients. Further research is needed to extend the cohort of paediatric CML patients who might achieve treatment-free remission with an ideal prerequisite of predicting the occurrence of molecular relapse l after imatinib cessation.
引用
- de Bruijn CMA, Millot F, Suttorp M, et al. Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study. Br J Haematol. 2019. PMID: 30843196. doi:10.1111/bjh.15826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。